189 related articles for article (PubMed ID: 10779023)
1. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas.
Marina NM; Poquette CA; Cain AM; Jones D; Pratt CB; Meyer WH
J Pediatr Hematol Oncol; 2000; 22(2):112-8. PubMed ID: 10779023
[TBL] [Abstract][Full Text] [Related]
2. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
[TBL] [Abstract][Full Text] [Related]
3. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Thomas D; Sylvester R; Van Oosterom A
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S13-6. PubMed ID: 3102089
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide nephrotoxicity in paediatric cancer patients.
Ashraf MS; Brady J; Breatnach F; Deasy PF; O'Meara A
Eur J Pediatr; 1994 Feb; 153(2):90-4. PubMed ID: 8157032
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide in pediatric solid tumors.
Carli M; Passone E; Perilongo G; Bisogno G
Oncology; 2003; 65 Suppl 2():99-104. PubMed ID: 14586158
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
Skinner R; Cotterill SJ; Stevens MC
Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
9. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
10. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
12. Tubular function and histological findings in ifosfamide-induced renal Fanconi syndrome--a report of two cases.
Rossi R; Helmchen U; Schellong G
Eur J Pediatr; 1992 May; 151(5):384-7. PubMed ID: 1396897
[TBL] [Abstract][Full Text] [Related]
13. [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
Stern N; Sakji I; Defachelles AS; Lervat C; Ryckewaert T; Marliot G; Peugniez C; Deplanque D; Penel N
Bull Cancer; 2017 Mar; 104(3):208-212. PubMed ID: 27986268
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Verwey J; Dombernowsky P; Onsrud M; Thomas D; Sylvester R
Eur J Cancer Clin Oncol; 1987 Mar; 23(3):311-21. PubMed ID: 3595691
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
Heideman RL; Douglass EC; Langston JA; Krischer JP; Burger PC; Kovnar EH; Kun LE; Friedman HS; Kadota R
J Neurooncol; 1995; 25(1):77-84. PubMed ID: 8523093
[TBL] [Abstract][Full Text] [Related]
17. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
Buesa JM; López-Pousa A; Martín J; Antón A; García del Muro J; Bellmunt J; Arranz F; Valentí V; Escudero P; Menéndez D; Casado A; Poveda A
Ann Oncol; 1998 Aug; 9(8):871-6. PubMed ID: 9789610
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
Meyer WH; Pratt CB; Poquette CA; Rao BN; Parham DM; Marina NM; Pappo AS; Mahmoud HH; Jenkins JJ; Harper J; Neel M; Fletcher BD
J Clin Oncol; 2001 Jan; 19(1):171-82. PubMed ID: 11134210
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
